The goal is not to place every patient on the newest or highest-dose medication
Retatrutide works by simultaneously activating three receptors involved in energy regulation and glucose metabolism: GLP-1 receptor agonism reduces appetite, slows gastric emptying, and enhances insulin secretion in a glucose-dependent manner
If you are still experiencing significant nausea, vomiting, or diarrhea at the end of a 4-week dose block, stay at the current dose for another 2-4 weeks before attempting the next increase
The process works in three main ways
Obesity and adipose tissue research Type 2 diabetes and insulin resistance Knee osteoarthritis Obstructive sleep apnea Non-alcoholic steatohepatitis (NASH) Key Findings from the Literature 01Phase 2: 24.2% mean weight loss at 48 weeks at highest dose 02Phase 3 TRIUMPH-4: 28.7% mean weight loss at 68 weeks 03Highest weight loss efficacy of any obesity pharmacotherapy in clinical trials to date 04Glucagon receptor agonism adds hepatic lipolysis absent from GLP-1-only agents 1 Independent third-party lab reports for this peptide
Retatrutide is a synthetic triple-agonist peptide designed for advanced biochemical research
